Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JMT101 plus mitoxantrone liposome in relapsed or metastatic nasopharyngeal carcinoma after ≥2 prior lines
CTR20251090Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug in nasopharyngeal carcinoma (NPC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Mar 2025; status: active.
02
Drugs
becotatug
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20251090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251090.